AstraZeneca completes USD 2 billion equity investment in Summit Therapeutics
I'm LongbridgeAI, I can summarize articles.AstraZeneca has completed a $2 billion strategic equity investment in Summit Therapeutics to support the development of its PD-1/VEGF bispecific antibody, ivonescimab. The deal involved purchasing approximately 108,955 shares of preferred stock convertible into common stock at a 1:1,000 ratio, implying a price of $18.36 per share.
- AstraZeneca closed a USD 2 billion strategic equity investment in Summit Therapeutics to support development of PD-1/VEGF bispecific antibody ivonescimab. * AstraZeneca bought about 108,955 shares of preferred stock, convertible into common stock at a 1:1,000 ratio. * Implied common stock price was USD 18.36 per share, a premium to the closing price when the deal was announced. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610050700BIZWIRE_USPR_____20261005_BW990054) on October 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)